Vysribli (previously Denosumab Intas) (Vysribli)
- Region
- 🇪🇺 EU
- Active substance
- Vysribli
- Company
- Intas Third Party Sales 2005 S.L.
- Status
- Authorised
- Therapeutic area
- Bone Resorption; Osteoporosis; Osteoporosis, Postmenopausal
- CHMP opinion
- Thu 18 Sep 2025
- EU approval
- Mon 17 Nov 2025
- Designations
- Biosimilar, Additional monitoring
- Application
- EMEA/H/C/006797
- ATC
- M05BX04
- Official record
- www.ema.europa.eu
Indication
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures. Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see section 5.1). In men with prostate cancer receiving hormone ablation, denosumab significantly reduces the risk of vertebral fractures. Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see section 5.1).
Regulatory milestones
Vysribli (previously Denosumab Intas) (Vysribli) approved in the EU
Marketing authorisation to Intas Third Party Sales 2005 S.L.; Biosimilar, Additional monitoring · source
Follow Vysribli (previously Denosumab Intas)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.